IL2 and neoplasm: The creation of a favorable host anti-tumor immune microenvironment by in situ delivery of interleukin-2 (IL-2) and granulocyte macrophage colony growth factor (GM-CSF) genes into the peri-tumoral site resulted in improved radio-responsiveness and systemic anticancer immunity [11].